Literature DB >> 27631961

Severe tophaceous gout and disability: changes in the past 15 years.

Carlos Omar López López1, Everardo Fuentes Lugo2, Everardo Alvarez-Hernández2, Ingris Peláez-Ballestas2, Rubén Burgos-Vargas2, Janitzia Vázquez-Mellado3.   

Abstract

Epidemiologic data from recent decades show a significant increase in the prevalence and incidence of gout worldwide, in addition to changes in its clinical expression. Our objective was to compare the frequency of the severity of gout and disability in two patient groups at our clinic during different periods. We included and compared data of two groups: group A (1995-2000), patients from previous report, and group B (2010-2014), the baseline data of current patients participating in a cohort (GRESGO). This evaluation included data of socioeconomic and educational levels, demographics, associated diseases, previous treatment, clinical and biochemical data, and disability evaluated using the Health Assessment Questionnaire (HAQ). We included data of 564 gout patients. Participants were 35.7 ± 12.7 years old at onset and had 12.0 ± 9.2-years disease duration at their first evaluation in our department. Group B patients were younger, had higher educational and socioeconomic levels, and had more severe disease. However, this group had less frequency of some associated diseases and significantly higher HAQ scores. With increased HAQ score, a higher number of acute flares and tender, limited-to-motion, and swollen joints were seen. The spectrum of gout has changed over the past decade. A higher percentage of our patients had a severe form of disease, were younger, had earlier disease onset, and had more disability reflected in higher HAQ scores. In our current patient group, the variable most associated with disability was limited-to-motion joints; however, the number of acute flares and tender and swollen joints was also higher in patients with greater disability.

Entities:  

Keywords:  Disability; Gout; HAQ; Tophaceous gout

Mesh:

Year:  2016        PMID: 27631961     DOI: 10.1007/s10067-016-3381-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Severe tophaceous gout. Characterization of low socioeconomic level patients from México.

Authors:  J Vázquez-Mellado; J Cruz; S Guzmán; J Casasola-Vargas; L Lino; R Burgos-Vargas
Journal:  Clin Exp Rheumatol       Date:  2006 May-Jun       Impact factor: 4.473

3.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study.

Authors:  Gianluca Trifirò; Paolo Morabito; Lorenzo Cavagna; Carmen Ferrajolo; Serena Pecchioli; Monica Simonetti; Elisa Bianchini; Gerardo Medea; Claudio Cricelli; Achille P Caputi; Giampiero Mazzaglia
Journal:  Ann Rheum Dis       Date:  2012-06-26       Impact factor: 19.103

5.  Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout.

Authors:  Taku Inokuchi; Zenta Tsutsumi; Sumio Takahashi; Tsuneyoshi Ka; Yuji Moriwaki; Tetsuya Yamamoto
Journal:  J Clin Rheumatol       Date:  2010-04       Impact factor: 3.517

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

7.  Gout, urate-lowering therapy, and uric acid levels among adults in the United States.

Authors:  Stephen P Juraschek; Lara C Kovell; Edgar R Miller; Allan C Gelber
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-04       Impact factor: 4.794

8.  Assessment of the dimensions, construct validity, and utility for rheumatoid arthritis screening of the COPCORD instrument.

Authors:  José Moreno-Montoya; José Alvarez-Nemegyei; Belem Trejo-Valdivia; Ingris Peláez-Ballestas
Journal:  Clin Rheumatol       Date:  2013-08-24       Impact factor: 2.980

9.  Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR).

Authors:  Carlo A Scire; Maria Manara; Marco A Cimmino; Marcello Govoni; Fausto Salaffi; Leonardo Punzi; Maria C Monti; Greta Carrara; Carlomaurizio Montecucco; Marco Matucci-Cerinic; Giovanni Minisola
Journal:  Arthritis Res Ther       Date:  2013-08-23       Impact factor: 5.156

10.  Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Christian Mallen; Weiya Zhang; Michael Doherty
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103

View more
  3 in total

1.  Seasonal variation in the internet searches for gout: an ecological study.

Authors:  Sinan Kardeş
Journal:  Clin Rheumatol       Date:  2018-10-29       Impact factor: 2.980

2.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

3.  Associated factors with functional disability and health-related quality of life in Chinese patients with gout: a case-control study.

Authors:  Ting Fu; Haixia Cao; Rulan Yin; Lijuan Zhang; Qiuxiang Zhang; Liren Li; Zhifeng Gu
Journal:  BMC Musculoskelet Disord       Date:  2017-11-03       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.